Esperion Therapeutics, Inc. (ESPR) Earnings History
Net Loss27 years of earnings data (1999–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Esperion Therapeutics, Inc. (ESPR) Earnings Overview
As of November 14, 2026, Esperion Therapeutics, Inc. (ESPR) reported trailing twelve-month net income of -$23M. The company earned $-0.11 per diluted share over the past four quarters.
Looking at the long-term picture, ESPR's historical earnings data spans multiple years. The company achieved its highest annual net income of -$11M in fiscal 1999.
Esperion Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including MDGL (-$155M net income, -30.1% margin), EWTX ($1.01B net income), PRTA (-$24M net income, -2520.6% margin), ESPR has comparable earnings metrics. Compare ESPR vs MDGL →
ESPR Earnings vs Peers
Earnings metrics vs comparable public companies
ESPR Historical Earnings Data (1999–2025)
19 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$23M | +56.2% | $60M | $-0.11 | -5.6% | 15.0% |
| 2024 | -$52M | +75.3% | $54M | $-0.28 | -15.6% | 16.4% |
| 2023 | -$209M | +10.4% | -$156M | $-2.03 | -179.9% | -133.7% |
| 2022 | -$234M | +13.2% | -$180M | $-4.33 | -309.6% | -237.8% |
| 2021 | -$269M | -87.5% | -$227M | $-11.03 | -343.0% | -289.0% |
| 2020 | -$144M | -47.7% | -$121M | $-6.05 | -63.1% | -53.3% |
| 2019 | -$97M | +51.9% | -$93M | $-4.02 | -65.5% | -62.8% |
| 2018 | -$202M | -20.9% | -$205M | $-7.54 | -109.4% | -110.9% |
| 2017 | -$167M | -122.7% | -$169M | $-6.98 | - | - |
| 2016 | -$75M | -50.6% | -$76M | $-3.33 | - | - |
| 2015 | -$50M | -36.9% | -$50M | $-2.26 | - | - |
| 2014 | -$36M | -39.4% | -$36M | $-2.22 | - | - |
| 2013 | -$26M | -122.2% | -$23M | $-1.70 | -0.5% | -0.5% |
| 2012 | -$12M | -8.5% | -$10M | $-1.22 | - | - |
| 2011 | -$11M | +62.3% | -$10M | $-1.13 | - | - |
| 2002 | -$29M | -15.2% | -$28M | $-6.86 | - | - |
| 2001 | -$25M | +9.6% | -$27M | $-6.38 | - | - |
| 2000 | -$28M | -158.4% | -$28M | $-9.35 | -1378800.0% | -1378600.0% |
| 1999 | -$11M | - | -$12M | $-7.94 | - | - |
Download Data
Export ESPR earnings history in CSV or JSON format
Free sign-in required to download data
ESPR Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
27+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ESPR — Frequently Asked Questions
Quick answers to the most common questions about buying ESPR stock.
What is ESPR earnings per share (EPS)?
ESPR trailing twelve-month (TTM) diluted EPS is $-0.11, reflecting N/A year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 1999 to 2025 is available in the table on this page.
What is Esperion Therapeutics, Inc.'s net income?
Esperion Therapeutics, Inc. (ESPR) trailing twelve-month net income is $-23M as of 2025. Earnings declined N/A year-over-year.
Is ESPR profitable?
ESPR is not currently profitable on a TTM basis, reporting a net loss of $-23M. Net margin is N/A. Investors should monitor for a return to profitability.
What is ESPR's earnings growth rate?
ESPR compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1999 to 2025.
What are ESPR's profit margins?
Esperion Therapeutics, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is N/A.
Is ESPR growing earnings?
ESPR TTM EPS: $-0.11. Net income: $-23M. YoY earnings change: N/A.
What was ESPR's best earnings year?
Esperion Therapeutics, Inc.'s highest annual net income on record is $-11M, achieved in fiscal year 1999. Earnings history on this page spans 1999 to 2025 and includes all annual and quarterly figures.
What were ESPR's earnings last quarter?
ESPR's most recent reported quarter was Q1 2026. Net income was $-25M with diluted EPS of $-0.10. For a full breakdown of all quarters, see the quarterly earnings table on this page.